Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice

Background: Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (EGFRm+). Head-to-head clinical...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in medical oncology 2021, Vol.13, p.17588359211012361-17588359211012361
Main Authors: Brückl, Wolfgang M., Reck, Martin, Griesinger, Frank, Schäfer, Harald, Kortsik, Cornelius, Gaska, Tobias, Rawluk, Justyna, Krüger, Stefan, Kokowski, Konrad, Budweiser, Stephan, Ficker, Joachim H., Hoffmann, Christopher, Schüler, Andrea, Laack, Eckart
Format: Article
Language:English
Subjects:
Adverse events
Clinical medicine
Clinical trials
Dosage
Epidermal growth factor
Epidermal growth factor receptors
Lung cancer
Metastases
Metastasis
Mutation
Non-small cell lung carcinoma
Original Research
Patients
Protein-tyrosine kinase
Small cell lung carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (EGFRm+). Head-to-head clinical trials have demonstrated superior efficacy with second-/third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) versus first-generation EGFR TKIs in EGFRm+ NSCLC. Data from routine clinical practice are necessary to confirm that clinical trial findings are transferable to real-world populations. Methods: In NCT02047903, a prospective non-interventional study in Germany, patients with EGFRm+ NSCLC received first-line afatinib until disease progression or intolerable adverse events. Key objectives were progression-free survival (PFS) rate at 12 months, objective response rate (ORR) and overall survival (OS). Safety/tolerability was also assessed. Results: Of 152 patients, 106 (69.7%) were female, 20 (13.1%) patients had an uncommon EGFR mutation and 51 patients (33.6%) had brain metastases. A starting dose of
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/17588359211012361